



### Cefzil® (cefprozil), Ceftin® (cefuroxime) – Indication Removal

- On November 22, 2016, the FDA announced the removal of the indication for secondary bacterial infection of acute bronchitis (SBIAB) from the [Cefzil \(cefprozil\)](#) and [Ceftin \(cefuroxime axetil\)](#) drug labels.
  - SBIAB was removed from the *Indications and Usage* and *Dosage and Administration* section of the Cefzil drug label.
  - SBIAB was removed from the *Indications and Usage*, *Dosage and Administration*, *Adverse Reactions* and *Clinical Studies* sections of the Ceftin drug label.
- Per the FDA, the revisions are necessary to furnish information needed for the safe use of these drugs, as the FDA no longer grants the indication of SBIAB.
- [Cefzil](#) is also indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of certain microorganisms for the following conditions: pharyngitis/tonsillitis, otitis media, acute sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated skin and skin-structure infections.
- [Ceftin](#) is also indicated for the treatment of the following infections due to susceptible bacteria: pharyngitis/tonsillitis, acute bacterial otitis media, acute bacterial maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, uncomplicated skin and skin-structure infections, uncomplicated urinary tract infections, uncomplicated gonorrhea, early Lyme disease, and impetigo.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.